Prostate Health
Natural health product licensed in Canada
- Other names
- Super Prostate
- Licence holder
- Bowen Biological Pharmaceuticals (Canada) Inc. Ltd.
- NPN or DIN-HM
- 80104481
- Status
- Inactive licence
- Licence date
- 21 September 2020
- Revision date
- Not provided
- Form
- Capsule, molle
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Dose déclarée au-delà d'une limite
Sélénium: up to 55 µg a day according to the dosing instructions published by Health Canada (1 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 50 µg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Zinc Source : Oxyde de zinc | 15 mg | 15,000 µg |
| Solanum lycopersicum Source : Chair (fruit) Extract : Matériel brut sec Extraction ratio : 50:1 Dry plant equivalent : 250 mg Potency : 6 % Lycopene | 5 mg | Not calculated |
| Sélénium Source : Produit de chélation de sélénium et de protéine végétale hydrolysée (PVH) | 55 microgram | 55 µg |
Non-medicinal ingredients
Gélatine, Lécithine, Cire d'abeille
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes de sexe masculin | minimum: 18 years | 1 Capsule | 1 Tous les jours |
Uses authorised in Canada
Saw palmetto is used in Herbal Medicine to help relieve the urologic symptoms (e.g. weak urine flow/incomplete voiding/frequent daytime/night time urination) associated with mild to moderate benign prostatic hyperplasia (BPH).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Effets indésirables connus
N/A.
- Contre-indications
N/A.
Source
Official Health Canada record, licence 80104481
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.